Extended solid tumour panel

Detection of five hundred and twenty-three oncogenic abnormalities in a single test.
Detection of NTRK1, NTRK2 and NTRK3 fusions. Tumor mutációs terhelés meghatározása.
Tumour mutation burden determination.

Precision oncology

The detection of clinically actionable mutations is the basis of precision oncology.
Tumor mutational burden and microsatellite instability are predictive biomarkers for immune checkpoint inhibitor treatments.
Comprehensive molecular studies are cost-effective and essential for new clinical studies.
In more than half of patients, a potentially drug-inducible molecular abnormality can be identified by multigene testing.
Comprehensive molecular studies are cost-effective and essential for new clinical studies.

For lung cancer, advanced tumours with an unfavourable prognosis, rare malignancies and metastases of unknown origin, it is worthwhile to perform comprehensive genetic testing early.

Mutation real frequency

CONTACT

+36 70 674 6611

PROJECT ORGANIZATION

project consultation, software demo, price quote, contract, organization

SAMPLE SUBMISSION

FFPE block or section, cell block, or smear, or isolated DNA

RESULT REPORTING

classification of variants according to international standards (pathogenic, likely pathogenic, VUS, etc.)

GENETIC ANALYSIS

bioinformatics analysis, identification and annotation of variants

HISTOLOGICAL PROCESSING

microscopic assessment of tumor cell number, DNA isolation

Method

From a formalin-fixed, paraffin-embedded (FFPE) block or other sample containing tumour cells.
Recommended tumour cell percentage: ≥20%
Sequencing of mutation hotspots and most common fusion transcripts of key oncogenes.
Identification of single nucleotide variants (SNVs), short insertions and deletions, copy number variations (CNVs) and fusion transcripts using bioinformatics methods.
Classification and annotation of identified variants (ClinVar, COSMIC, HGMD, Varsome, etc.)